Eli Lilly Announces $15 Billion Share Repurchase Program and 15% Dividend Increase Driven by Zepbound Success

Gelonghui December 10 | Eli Lilly and Company announced on Monday that the board had approved a stock repurchase plan of up to 15 billion U.S. dollars, reflecting the growth momentum driven by the blockbuster weight-loss drug Zepbound. Meanwhile, the company will increase its quarterly dividend by 15%.